What is the current Benign Prostatic Hyperplasia Testing market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Benign Prostatic Hyperplasia Testing market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Benign Prostatic Hyperplasia Testing market?

Increasing prevalence of BPH and advancements in diagnostic technologies are key drivers.

What are the major challenges faced by the Benign Prostatic Hyperplasia Testing market?

High costs and limited awareness are major challenges in the market.

Which regions are the leaders in the Benign Prostatic Hyperplasia Testing market?

North America and Europe are the leading regions in the market.

Who are the top companies in the Benign Prostatic Hyperplasia Testing market?

Top companies include Abbott, Siemens, and Roche, among others.

What are the future opportunities in the Benign Prostatic Hyperplasia Testing market?

Emerging markets and innovative diagnostic technologies offer future opportunities.

How is technology impacting the Benign Prostatic Hyperplasia Testing market?

Advances in imaging and biomarker technologies are improving diagnostic accuracy.

What is the current regulatory landscape for the Benign Prostatic Hyperplasia Testing market?

Regulatory bodies are implementing guidelines for diagnostic test approvals and usage.

What is the future outlook for the Benign Prostatic Hyperplasia Testing market?

The market is expected to witness significant growth due to increasing demand.

Benign Prostatic Hyperplasia Testing Market Metrics & Forecast Analysis 2033

Benign Prostatic Hyperplasia Testing by Application (Hospitals, Diagnostic Centers, Clinics, Research Institutes), by Types (Urinalysis, Prostate-Specific Antigen (PSA) Blood Test, Urodynamic Test, Cystoscopy), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Benign Prostatic Hyperplasia Testing Market Size | CAGR 5.2 Forecast 2033

Benign Prostatic Hyperplasia Testing Market Metrics & Forecast Analysis 2033

🏭 Healthcare🌍 Global

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 97

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 5.2%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Benign Prostatic Hyperplasia Testing Market Overview

The Benign Prostatic Hyperplasia Testing market refers to the industry focused on diagnosing and treating Benign Prostatic Hyperplasia (BPH), a common condition affecting older men. As the global population ages, the Benign Prostatic Hyperplasia Testing market size is expected to reach $3.4 billion by 2026, with a growth outlook that is increasingly positive due to rising awareness and advancements in diagnostic technologies. The market forecast indicates a significant expansion, driven by the growing prevalence of BPH and the need for effective diagnostic and treatment options, with the global industry expansion expected to be fueled by technological shifts, regulatory developments, and changing consumer behavior.

Loading chart…

The Benign Prostatic Hyperplasia Testing market is expected to grow at a CAGR of 7.5% from 2026 to 2033, driven by macro drivers such as the increasing prevalence of BPH, advancements in diagnostic technologies, and rising awareness about the condition. Key forces shaping the industry include technology shifts towards non-invasive and minimally invasive diagnostic tests, regulatory developments focused on ensuring the safety and efficacy of diagnostic devices, and changing consumer behavior driven by rising healthcare awareness and increasing demand for effective treatments. The largest region in the Benign Prostatic Hyperplasia Testing market is North America, while the fastest-growing region is expected to be Asia-Pacific, driven by the growing healthcare infrastructure and increasing awareness about BPH in the region.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.80 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AEternaZentaris; Astellas Pharma; Eli Lilly and Company; IntelGenx Technologies Corp; Nymox Pharmaceutical Corporation; Protox Therapeutics; Quest PharmaTech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Benign Prostatic Hyperplasia Testing market is poised for significant growth, driven by an increasing awareness of the condition and advancements in diagnostic technologies. The Benign Prostatic Hyperplasia Testing market size is expected to expand substantially, with a promising growth forecast that underscores the potential for innovation and investment in this space.

Growth Drivers2 items

Advances in medical technology, such as the development of more accurate and non-invasive diagnostic tests, are driving growth in the Benign Prostatic Hyperplasia Testing market. This has improved the ability to detect the condition early, leading to better patient outcomes and increased demand for testing services.

The rising prevalence of Benign Prostatic Hyperplasia (BPH) due to an aging population and lifestyle factors is another key driver of market growth. As the population ages, the incidence of BPH is expected to increase, fueling demand for diagnostic tests and treatments.

Restraints2 items

High costs associated with certain diagnostic tests and treatments for BPH can limit access to care, particularly in regions with underdeveloped healthcare systems. This can restrain market growth by reducing the overall demand for testing services.

Regulatory hurdles, including the need for approvals and compliance with stringent safety and efficacy standards, can slow the introduction of new diagnostic technologies to the market. This can delay the realization of market potential for innovative testing solutions.

Opportunities2 items

The development of point-of-care diagnostic tests that are rapid, accurate, and cost-effective presents a significant opportunity for expansion in the Benign Prostatic Hyperplasia Testing market. Such tests can increase access to care and improve patient outcomes by facilitating earlier diagnosis and treatment.

Emerging markets, particularly in Asia-Pacific and Latin America, offer untapped opportunities for growth due to their large and growing populations and increasing awareness of BPH. Companies can capitalize on these opportunities by adapting their products and services to meet local needs and regulatory requirements.

Challenges2 items

The Benign Prostatic Hyperplasia Testing market faces challenges related to reimbursement policies and healthcare funding. Variability in coverage and reimbursement rates for diagnostic tests can affect market growth by influencing the demand for certain services.

Ensuring the accuracy and reliability of diagnostic tests is a critical challenge. Any issues with test performance can lead to misdiagnosis, inappropriate treatment, and erosion of trust in the market, ultimately affecting the growth forecast of the Benign Prostatic Hyperplasia Testing market.

Market Segmentation

Loading chart…

The Application segment in the Benign Prostatic Hyperplasia Testing market refers to the various uses of testing methods for diagnosing and monitoring Benign Prostatic Hyperplasia (BPH). This segmentation category contributes significantly to the overall market size, as it encompasses a wide range of applications, including clinical diagnosis, disease monitoring, and research purposes. Understanding the Benign Prostatic Hyperplasia Testing segmentation by application is crucial for market players to identify areas of growth and opportunity.

The Types segment in the Benign Prostatic Hyperplasia Testing market is further divided into subtypes, including [object Object] and [object Object]. These subtypes represent different testing methods, such as digital rectal examination, prostate-specific antigen (PSA) test, and imaging tests. Each subtype has its own market share and growth prospects, and analyzing these subtypes is essential for understanding the overall market taxonomy and identifying trends in the Benign Prostatic Hyperplasia Testing market.

Benign Prostatic Hyperplasia Testing Segmentation Breakdown10 items

Application

Hospitals

Diagnostic Centers

Clinics

Research Institutes

Types

Urinalysis

Prostate-Specific Antigen (PSA) Blood Test

Urodynamic Test

Cystoscopy

Regional Insights

Loading chart…

The Benign Prostatic Hyperplasia Testing market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of advanced diagnostic technologies, favorable government policies, and growing investments in healthcare infrastructure.

Key drivers in North America include high disease prevalence, well-established healthcare infrastructure, and reimbursement policies. In Europe, drivers include rising awareness about Benign Prostatic Hyperplasia, expanding healthcare services, and technological advancements. Asia Pacific is driven by growing demand for diagnostic services, increasing healthcare expenditure, and improving ecosystem maturity. Latin America and Middle East & Africa are driven by expanding healthcare access, growing patient population, and rising awareness about the disease.

The regional forecast indicates that North America will maintain its dominance, while Asia Pacific will experience rapid growth due to demographic changes, infrastructure development, and increasing adoption of Benign Prostatic Hyperplasia Testing technologies. Understanding these regional dynamics is crucial for stakeholders to navigate the Benign Prostatic Hyperplasia Testing market and capitalize on emerging opportunities.

Competitive Landscape

The Benign Prostatic Hyperplasia Testing market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. The Benign Prostatic Hyperplasia Testing competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies concentrate on pricing and distribution.

Common strategies employed by key players include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have adopted distinct strategies:

AEternaZentaris: regional expansion

Astellas Pharma: innovation pipeline

Eli Lilly and Company: premium pricing

IntelGenx Technologies Corp: OEM tie-ups

Nymox Pharmaceutical Corporation: local manufacturing

Protox Therapeutics: vertical integration

Key Benign Prostatic Hyperplasia Testing Companies7 items

AEternaZentaris

Astellas Pharma

Eli Lilly and Company

IntelGenx Technologies Corp

Nymox Pharmaceutical Corporation

Protox Therapeutics

Quest PharmaTech

Market Ecosystem

The Benign Prostatic Hyperplasia Testing ecosystem spans across upstream, midstream, and downstream segments, encompassing technology providers, integrators, channels, and end users. This ecosystem is characterized by the creation and capture of value through the development, manufacturing, and distribution of testing products and services. The value chain analysis of this ecosystem reveals the intricate relationships between various participants, influencing the adoption and accessibility of Benign Prostatic Hyperplasia Testing solutions.

Raw material/component suppliers — providing diagnostic reagents

OEMs / manufacturers — producing testing equipment

Technology providers — developing diagnostic software

System integrators / EPCs — integrating testing systems

Distributors / channel partners — supplying testing products

Service providers / after-sales — offering maintenance services

Regulators/standards bodies — establishing testing standards

The flow of value within the Benign Prostatic Hyperplasia Testing ecosystem is influenced by control points, such as regulatory approvals and standards, which can create bottlenecks and impact the adoption of testing solutions. Dependency risks, including input constraints and switching costs, can also affect the ecosystem's dynamics. Furthermore, partnerships and interoperability requirements between ecosystem participants can either facilitate or hinder the exchange of value. The ecosystem's characteristics may differ by region, with varying levels of access to testing products and services, and distinct regulatory frameworks governing the industry.

Recent Industry Insights

The Benign Prostatic Hyperplasia Testing industry trends have witnessed significant developments over the last 12-18 months. Recent partnerships, such as the collaboration between major pharmaceutical companies and specialized diagnostic firms, have focused on improving diagnostic accuracy and patient outcomes. Furthermore, the industry has seen notable mergers and acquisitions, with leading healthcare companies expanding their portfolios to include innovative Benign Prostatic Hyperplasia testing solutions.

Additionally, there have been several product launches and technological advancements in the field, including the introduction of non-invasive testing methods and advanced imaging techniques. These developments have not only enhanced the diagnosis and treatment of Benign Prostatic Hyperplasia but also contributed to the growth of the Benign Prostatic Hyperplasia Testing industry. Regulatory changes and shifts in consumer trends have also played a crucial role in shaping the industry, with an increased emphasis on patient-centric care and personalized medicine.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Benign Prostatic Hyperplasia Testing market outlook. The market attractiveness is moderate, driven by an increasing prevalence of Benign Prostatic Hyperplasia (BPH) and advancements in diagnostic technologies. Competitive intensity is high, with key players investing in research and development to improve diagnostic accuracy and patient outcomes. The long-term outlook is positive, with the market expected to grow due to an aging population and rising awareness about BPH. The innovation landscape is evolving, with emerging technologies such as artificial intelligence and machine learning being explored for improved diagnosis and treatment. Demand-supply balance is stable, with key players ensuring adequate supply of diagnostic tests and treatments. Key risk factors include regulatory changes and reimbursement challenges, which may impact market growth.

11 items

1. Executive Summary

2. Benign Prostatic Hyperplasia Testing Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Benign Prostatic Hyperplasia Testing Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Benign Prostatic Hyperplasia Testing Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals

6.1.2. Diagnostic Centers

6.1.3. Clinics

6.1.4. Research Institutes

6.2. Global Benign Prostatic Hyperplasia Testing Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Urinalysis

6.2.2. Prostate-Specific Antigen (PSA) Blood Test

6.2.3. Urodynamic Test

6.2.4. Cystoscopy

6.3. Global Benign Prostatic Hyperplasia Testing Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Benign Prostatic Hyperplasia Testing Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Benign Prostatic Hyperplasia Testing Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Benign Prostatic Hyperplasia Testing Market Competition by Key Manufacturers

8.1. Global Benign Prostatic Hyperplasia Testing Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Benign Prostatic Hyperplasia Testing: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. AEternaZentaris

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Astellas Pharma

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eli Lilly and Company

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. IntelGenx Technologies Corp

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Nymox Pharmaceutical Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Protox Therapeutics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Quest PharmaTech

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Benign Prostatic Hyperplasia Testing Market

Figure 4: Global Benign Prostatic Hyperplasia Testing Market: Drivers

Figure 5: Global Benign Prostatic Hyperplasia Testing Market: Challenges

Figure 6: Global Benign Prostatic Hyperplasia Testing Market: Trends

Figure 7: Global Benign Prostatic Hyperplasia Testing Market: Opportunity

Figure 8: Global Benign Prostatic Hyperplasia Testing Market: Restraint

Figure 9: Global Benign Prostatic Hyperplasia Testing Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Benign Prostatic Hyperplasia Testing Market Value (USD Million) By Region

Figure 15: Global Benign Prostatic Hyperplasia Testing Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Benign Prostatic Hyperplasia Testing Market Value (USD Million) By Region

Figure 23: Global Benign Prostatic Hyperplasia Testing Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

67 items

Table 1: Market Segmentation Analysis

Table 2: Global Benign Prostatic Hyperplasia Testing Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Benign Prostatic Hyperplasia Testing Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Benign Prostatic Hyperplasia Testing Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Benign Prostatic Hyperplasia Testing Market Value (USD Million) By Region

Table 10: Global Benign Prostatic Hyperplasia Testing Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Benign Prostatic Hyperplasia Testing Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Benign Prostatic Hyperplasia Testing Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Benign Prostatic Hyperplasia Testing Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: AEternaZentaris Basic Information And Sales Area

Table 31: AEternaZentaris. Products Portfolio

Table 32: Astellas Pharma Basic Information And Sales Area

Table 33: Astellas Pharma. Products Portfolio

Table 34: Eli Lilly and Company Basic Information And Sales Area

Table 35: Eli Lilly and Company. Products Portfolio

Table 36: IntelGenx Technologies Corp Basic Information And Sales Area

Table 37: IntelGenx Technologies Corp. Products Portfolio

Table 38: Nymox Pharmaceutical Corporation Basic Information And Sales Area

Table 39: Nymox Pharmaceutical Corporation. Products Portfolio

Table 40: Protox Therapeutics Basic Information And Sales Area

Table 41: Protox Therapeutics. Products Portfolio

Table 42: Quest PharmaTech Basic Information And Sales Area

Table 43: Quest PharmaTech. Products Portfolio

Table 44: Global Market Value (USD Million) (2025-2032) By Application

Table 45: Global Market Share (%) By Application (2032)

Table 46: Global Market Value (USD Million) (2025-2032) By Types

Table 47: Global Market Share (%) By Types (2032)

Table 48: Global Benign Prostatic Hyperplasia Testing Market Value (USD Million) By Region

Table 49: Global Benign Prostatic Hyperplasia Testing Market Share (%) By Region (2025-2032)

Table 50: North America Market Value (USD Million) (2025-2032) By Country

Table 51: North America Market Value (USD Million) (2025-2032) By Application

Table 52: North America Market Value (USD Million) (2025-2032) By Types

Table 53: Europe Market Value (USD Million) (2025-2032) By Country

Table 54: Europe Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Types

Table 56: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 57: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 59: South America Market Value (USD Million) (2025-2032) By Country

Table 60: South America Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Types

Table 62: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 63: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 65: Research Programs/Design For This Report

Table 66: Key Data Information From Secondary Sources

Table 67: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Benign Prostatic Hyperplasia Testing Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.80 billion
Growth rate	CAGR of 5.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	AEternaZentaris; Astellas Pharma; Eli Lilly and Company; IntelGenx Technologies Corp; Nymox Pharmaceutical Corporation; Protox Therapeutics; Quest PharmaTech
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options